Skip to content

The Lack of Clinical Trials in the Medical Marijuana Industry

The Lack of Clinical Trials in the Medical Marijuana Industry

As time goes on, medical marijuana is starting to break barriers in various states across the country. Out of the 50 states, 33 have approved a comprehensive medical marijuana program (NCSL). Currently, marijuana, medical or recreational, is illegal at the federal level, despite legalization in various states. Many medical professionals are interested in prescribing medical marijuana to patients with a qualifying condition, but most feel they don’t have sufficient knowledge or feel comfortable to do so. This lack of knowledge is a direct result of the lack of clinical trials in the medical marijuana industry, but why is that the case?

The Problem

The biggest problem surrounding why it’s so difficult for scientists to get clinical trials up and running is the continuation of roadblocks that federal laws create. Even though medical marijuana may be legalized in some states, scientists are still having a significantly harder time conducting research on the medicinal benefits of this “illicit drug”. Without sufficient research, we can expect the legalization of marijuana at the federal level, even for medicinal uses, to be a steep uphill battle.

Under federal law, cannabis is on the same level as controlled substances, like cocaine and heroin. Every controlled substance is classified by schedule based on relative potential for abuse and medicinal value. Under the CSA, cannabis is classified as a Schedule 1 drug, meaning the federal government views cannabis as highly addictive and having no medical value. (SafeAccessNow.org)

These strict federal laws can make it more difficult for researchers to legally obtain the necessary supply of marijuana for their trials. The difficulty of obtaining a legal supply puts any planned research at a hard stop with no chance of moving forward. Essentially, we’re currently experiencing a catch-22, with the federal government refusing to legalize marijuana based on its Schedule 1 standing and the need to obtain marijuana legally for clinical trials to prove this view unsound.

In fact, if one were to conduct a clinical trial, they would have an easier time conducting research on drugs such as ecstasy or magic mushrooms. Clinical researchers can request the ability to grow or create restricted compounds, including LSD, MDMA or psilocybin, in their lab from the DEA. Unfortunately, this is not the case with cannabis.

As expected, these classifications and restrictions on marijuana are causing a variety of frustrations across the medical community. Many researchers have noted that research is “hindered by a complicated federal approval process, limited availability of research grad marijuana and the debate over legalization.” (SafeAccessNow.org) Although we have these restrictions by the federal government, scientists are still working towards the ability to conduct sufficient research on marijuana and will continue their efforts as much as possible while following the law.

What’s an Alternative?

Since it can be difficult to locate information about the safety and effect of cannabis on the human body, how are physicians supposed to know if prescribing medical marijuana is right for their patients? Enter: Arfinn Med. Many physicians who believe in the therapeutic power of medical marijuana are beginning to try alternative treatment plans with their patients. Arfinn Med provides a portal for these physicians to track and store data to be analyzed. Additionally, physicians have the ability to consult and connect with a nationwide network of medical professionals to discuss actual experiences regarding patient outcomes.

If you are a licensed medical professional and interested in gaining more data on medical marijuana or and what it can do for your patients, join Arfinn Med for FREE today! Let us help you start treating your patients with the power of data on your side.  

Sources: http://www.ncsl.org/research/health/state-medical-marijuana-laws.aspx

https://www.safeaccessnow.org/federal_marijuana_law

https://www.safeaccessnow.org/medical_cannabis_research_what_does_the_evidence_say

https://www.cmcr.ucsd.edu/

Stories you may be interested in

State Board of Health reviews timelines for establishing Mississippi medical marijuana program

JACKSON, Miss. (WLBT) – The blueprint for Mississippi’s medical marijuana program is Initiative 65 that voters approved in November. That contains detailed requirements and the clock is ticking to get it started. The State Board of Health met virtually Wednesday to discuss the groundwork of the medical marijuana program. “I do want to tell you…
Read More

States with medical marijuana laws saw 20 percent drop in some opioid prescriptions

States with active medical marijuana laws saw certain opioid prescription rates drop nearly 20 percent compared to states without medical marijuana programs, according to a first-of-its-kind study out of Columbia University’s Irving Medical Center. Authors said the findings underscore the importance of providing patients with pain management alternatives, such as cannabis, in efforts to reduce…
Read More

Medical Marijuana Faces Acceptance Barrier by Hesitant Medical Schools

A new study shows a growing interest by university pharmacy programs in teaching about medical marijuana in their curriculum, while medical schools seem to lag behind. Sixty-two percent of U.S. pharmacy school respondents queried in a new survey said they included medical marijuana in their doctorate of pharmacy curriculum. That’s according to a nine-page study co-authored by…
Read More

More baby boomers use medical marijuana, but they want their doctors to get wise to the risks and benefits

Baby boomers’ marijuana use has edged upward in the past decade, but recent research suggests some still have a hard time getting a hold of the drug. Older adults want more education, more research and greater openness with their health-care providers about using medical marijuana, according to a qualitative study of older cannabis users and non-users in…
Read More

Medical Cannabis and Breast Cancer

October is breast cancer awareness month and we at Arfinn Med would like to reiterate the importance of early screening and regular tests.  According to the American Cancer Society: “Breast cancer is the most common cancer in American women, except for skin cancers. Currently, the average risk of a woman in the United States developing breast…
Read More

New approach to medical marijuana coming ‘very soon,’ DeSantis says

TALLAHASSEE — With one of his chief advisers tweeting the hashtag “NoSmokeIsAJoke,” Gov. Ron DeSantis said Monday he will “very soon” announce changes in how the state is carrying out a constitutional amendment that broadly legalized medical marijuana. Read the full story here.
Read More